Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
ImmunityBio, Inc. (NASDAQ:IBRX) stands against stocks that stand strong amid cautious market environment. The stock market showed resilience on Wednesday, with all major indices ending in the green territory anew, as investors weighed news of President Donald Trump's imposition of a new round of tariffs while digesting minutes of the Federal Reserve. The Dow Jones rose by 0.16 percent, the S&P 500 increased by 0.24 percent, while the tech-heavy Nasdaq eked out a 0.07 percent gain. Despite the news, ten companies managed to stand out, posting modest gains during the trading session. To come up with Wednesday's top performers, we considered only the stocks with more than $1.9 billion in market capitalization and $5 million in daily trading volume. Note that some stocks we have covered in-depth over the past few days have been excluded from this list. Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? A technician analyzing natural killer cells, as part of an immune system
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (NASDAQ:IBRX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder CancerBusiness Wire
- Should EMA's Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 12/15/25 - Form 8-K
- 12/12/25 - Form 8-K
- 11/10/25 - Form SCHEDULE
- IBRX's page on the SEC website